Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.

Khamisi, Selwan; Anders Karlsson, F; Ljunggren, Östen; Thulin, Mans; Larsson, Anders

Khamisi, Selwan; Anders Karlsson, F; Ljunggren, Östen; Thulin, Mans; Larsson, Anders.

Afiliação

Khamisi S; Department of Medical Sciences, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Anders Karlsson F; Department of Medical Sciences, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Ljunggren Ö; Department of Medical Sciences, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Thulin M; Department of Statistics, Uppsala University, Uppsala, Sweden.
Larsson A; Department of Medical Sciences, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden. Electronic address: anders.larsson@akademiska.se.

Cytokine ; 169: 156269, 2023 09.

Article em En | MEDLINE | ID: mdl-37307688

Assuntos

Doença de Graves; Oftalmopatia de Graves; Hipertireoidismo; Humanos; Antígeno B7-H1; Fator de Crescimento de Fibroblastos 23

Palavras-chave

Cytokines; FGF-23; Graves' disease; Graves' ophthalmopathy; Humans; Orbit/metabolism/pathology programmed cell death 1 receptor/metabolism; Thyroid associated ophthalmopathy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Graves / Oftalmopatia de Graves / Hipertireoidismo Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google